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Objective
To determine the factors associated with false-negative re-
sults on sentinel node biopsy and sentinel node localization
(identification rate) in patients with breast cancer enrolled in a
multicenter trial using a combination technique of isosulfan
blue with technetium sulfur colloid (Tc99).
Summary Background Data
Sentinel node biopsy is a diagnostic test used to detect
breast cancer metastases. To test the reliability of this
method, a complete lymph node dissection must be per-
formed to determine the false-negative rate. Single-institution
series have reported excellent results, although one multi-
center trial reported a false-negative rate as high as 29% us-
ing radioisotope alone. A multicenter trial was initiated to test
combined use of Tc99 and isosulfan blue.
Methods
Investigators (both private-practice and academic surgeons)
were recruited after attending a course on the technique of
sentinel node biopsy. No investigator participated in a learning
trial before entering patients. Tc99 and isosulfan blue were
injected into the peritumoral region.
Results
Five hundred twenty-nine patients underwent 535 sentinel
node biopsy procedures for an overall identification rate in
finding a sentinel node of 87% and a false-negative rate of
13%. The identification rate increased and the false-negative
rate decreased to 90% and 4.3%, respectively, after investi-
gators had performed more than 30 cases. Univariate analysis
of tumor showed the poorest success rate with older patients
and inexperienced surgeons. Multivariate analysis identified
both age and experience as independent predictors of failure.
However, with older patients, inexperienced surgeons, and
patients with five or more metastatic axillary nodes, the false-
negative rate was consistently greater.
Conclusions
This multicenter trial, from both private practice and aca-
demic institutions, is an excellent indicator of the general
utility of sentinel node biopsy. It establishes the factors that
play an important role (patient age, surgical experience,
tumor location) and those that are irrelevant (prior surgery,
tumor size, Tc99 timing). This widens the applicability of
the technique and identifies factors that require further
investigation.
Since the description of sentinel lymph node biopsy
(SNB) in the early 1990s, results for breast cancer have been
reported in several single-institution series.1–4 These results
were promising, and the sentinel node predicted the pres-
ence or absence of disease in the remaining axillary lymph
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nodes in most patients. Techniques varied in these trials,
using isosulfan blue (IB) alone, technetium sulfur colloid
(Tc99) alone, or both combined. The only multicenter trial
validating this new surgical technique used Tc99 alone.5
Other series involving large number of patients using IB and
Tc99 combined have been criticized for either failing to
report an accurate false-negative rate6 or not permitting
calculation of this rate by enrolling patients who did not
undergo complete lymph node assessment.4
The impetus to perform SNB alone is great, because there
are no data to support the contention that patients without
axillary metastases will benefit from the potentially morbid
procedure of axillary dissection. Unfortunately, as SNB
moves to replacing axillary node dissection, the opportunity
to obtain accurate data on the false-negative rate under
various conditions is lost. The studies to date have tightly
restricted the conditions under which lymphatic mapping is
performed (i.e., size of tumor, timing of Tc99, and prior
breast surgery). There is little information, however, to
support the premise that these factors actually affect the
diagnostic accuracy of the technique.
Before moving to performing SNB alone as the standard
of care for patients with breast cancer, it will be important
to determine which patients can benefit as well as which
may be ill served by the technique. Patients must undergo
complete axillary node dissection to determine the false-
negative rate under various conditions to determine which
patients are appropriate candidates for SNB. The purpose of
this trial was to determine the factors that influence lym-
phatic mapping in a multicenter trial by performing SNB
followed by complete lymph node dissection.
METHODS
A multicenter trial was conducted from February 1997
through May 1999 and enrolled patients from surgical in-
vestigators who participated in a formal lymphatic mapping
and SNB course. The course included hands-on experience
in a porcine model that has previously been described.7 The
principal investigator visited most investigative sites at least
once. Institutional review board approval was obtained from
all investigative sites, and all patients gave informed con-
sent. Investigative sites included both private-practice set-
tings and academic centers.
The technique of SNB included a peritumoral injection with
2 to 5 mL IB (American Regent Laboratories, Inc., Shirley,
NY) and a peritumoral injection of 1 mCi (37MBq) Tc99
(CIS-US, Bedford, MA). The Tc99, in a volume of 4 mL, was
injected at 12, 3, 6, and 9 o’clock positions around the tumor,
biopsy site, or lumpectomy cavity. Each investigative site had
a choice of using filtered or unfiltered Tc99. Filtered Tc99 was
obtained by passing radiocolloid over a 0.2-mm filter. Only the
timing of IB injection was restricted, and it was injected
immediately before surgery. Intraoperative use of the gamma
probe was required on all patients to aid in the identification of
the sentinel node. A sentinel node was defined as any node that
was blue, both blue and hot (with hot defined as an ex vivo
count of 10 times the background count or more), or hot only
node, and the location of all sentinel nodes in vivo was re-
corded. The background count was taken from the lower
extremity or abdomen. Gamma probe counts were obtained on
the axillary dissection specimen, all surrounding nodal basins,
the primary injection site, and the sentinel nodes in vivo and ex
vivo. In most cases the sentinel node was harvested before
performing the definitive surgery on the breast. A standard
level 1 and 2 lymph node dissection was performed after
sentinel node excision.
Exclusion criteria for patients were clinically suspicious
or positive axillary nodes, pregnancy, and extensive cardiac,
pulmonary, or renal disease. Data collected during surgery
included the type of gamma probe used (C-track [Carewise,
Morgan Hill, CA], Neoprobe [Neoprobe Corp., Dublin, OH],
and Navigator [U.S. Surgical, Bedford, OH]), technique of
diagnosis (including patients undergoing prior lumpectomy,
open biopsy, fine-needle aspiration biopsy, or core biopsy),
tumor size, time of Tc99 injection, time of sentinel node
harvest, and use of filtered versus unfiltered Tc99.
A radiation safety officer participated in the start-up of
the protocol at each site. Radiation exposure was monitored
in the radiology suite, the operating room, and the pathology
laboratory. The primary tumor or site of Tc99 injection was
kept for 24 to 48 hours before pathologic analysis to allow
sufficient decay.
All sentinel nodes were serially sectioned, and every
other section was submitted for additional laboratory stud-
ies. Each section sent to pathology was analyzed using
multiple sections. The majority of hematoxylin-and-eosin–
negative nodes were analyzed by immunohistochemistry
with a cytokeratin cocktail (Cytokeratin AE1:3; Boehringer
Mannheim Corp., Indianapolis, IN).
The Fisher exact test for nominal variables was used to
compare success rates and false-negative rates according to
surgeon experience, patient age, tumor size, location of the
primary tumor, histologic tumor type, type of previous
biopsy, filtered or unfiltered Tc99, time from injection to
surgery, number of positive nodes, number of sentinel nodes
found, type of gamma probe used, and ex vivo sentinel node
counts. Any variables that had a probability value of less
than 0.25 were used to develop a multivariate logistic re-
gression model to predict failure to find a sentinel node. The
Hosmer–Lemeshow goodness-of-fit criterion was used to
determine the adequacy of the model. The identification rate
in this trial is defined as the ability to identify a sentinel
node successfully on a per-procedure basis (a few patients
underwent bilateral SNB). The false-negative rate was de-
fined as the number of procedures with a negative sentinel
node (and a positive nonsentinel node) divided by the pro-
cedures with positive axillary lymph nodes. A one-way
analysis of variance was used to compare the mean number
of nodes found and mean ex vivo counts between injection
intervals, type of previous biopsy, and filtered or unfiltered
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Tc99. The Fisher exact test was used to assess the relation
between the number of sentinel nodes found and the number
of those nodes that were positive. SPSS 8.0 statistical soft-
ware (SPSS, Inc., Chicago, IL) was used for the statistical
analysis. All reported probability values for the Fisher exact
test were two-tailed.
RESULTS
A total of 529 patients were enrolled in the study. The
mean number of lymph nodes obtained during axillary
dissection was 13 6 6. Forty-eight surgeons participated in
the trial and contributed a median of 18 patients each.
Characteristics of the study population are summarized in
Table 1. Most of the patients had upper outer quadrant
lesions and pathology consistent with infiltrating ductal
carcinoma and underwent lumpectomy (341 [70%]) versus
mastectomy (146 [30%]). The mean age of the entire group
was 57 years (range 26–89). Six patients underwent bilat-
eral SNB for bilateral breast cancer. Sixteen percent of
patients were found to have an internal mammary basin
count greater than background but SNB was not performed,
although the option was available to the investigators. Table
2 presents the status of the lymph nodes in all SNB proce-
dures where a sentinel node was found. Of the 535 SNB
procedures, a sentinel node was identified in 466, for an
identification rate of 87%. The false-negative rate for the
group was 13%. The accuracy of the sentinel nodes to detect
metastatic disease was 96%, and the negative predictive
value was 95%. Forty-six patients were excluded from the
false-negative analysis for lack of a complete lymph node
dissection, but they were included in analysis of success (or
identification) rates.
A univariate analysis that examined eight variables (Ta-
ble 3) found that only patient age (50 years or older) and
surgeon experience (performance of fewer than 10 cases)
significantly affected the identification rate of finding the
sentinel node. Identification rates were lower in patients
who had a prior lumpectomy, five or more positive lymph
nodes on axillary dissection, lesions in the medial quadrant,
or Tc99 timing intervals less than 30 minutes, but these did
not reach statistical significance. A multivariate analysis
showed that surgeon experience and age were independent
predictors of failed SNB (Table 4).
The number of false-negative results was small (n 5 18).
A univariate analysis examined nine variables to determine
their influence on the false-negative rate (Table 5). Al-
though the false-negative rate was high among inexperi-
enced surgeons and procedures yielding only one sentinel
node, only the location of a tumor in the inner quadrant
reached statistical significance. Additional analysis indi-
cated that the location effect could not be explained on the
basis of variation in the average number of sentinel nodes
found between locations.
Fourteen patients in the trial received preoperative che-
motherapy. There were no false-negative results, and a
sentinel node was identified in each patient. Lymphovascu-
lar invasion data were available in 284 patients. The success
rate was 80% in the 50 patients with this tumor character-
istic versus 87% in patients whose tumors lacked lympho-
vascular invasion (P 5 NS).
Figure 1 shows the false-negative rates and identification
rates for increasing patient age: the success rate steadily de-
creased and the false-negative rate varied widely over these
age groups. With increasing surgeon experience, the false-
negative rate decreased and the identification rate increased
(Fig. 2).
A total of 1,055 sentinel nodes were found (mean 2.2 6
1.4 per patient). Most patients had either one (41%) or two
Table 1. PATIENT CHARACTERISTICS
Characteristic Groups # Pts. (%)
Tumor type Infiltrating ductal 393 (74%)
Infiltrating lobular 36 (7%)
Other 92 (16%)
Unknown 14 (3%)
Tumor location Upper outer quadrant 244 (46%)
Upper inner quadrant 66 (12%)
Lower outer quadrant 45 (8%)
Lower inner quadrant 39 (7%)
Central 56 (11%)
Other 70 (13%)
Unknown 15 (3%)
Tumor size ,2 cm 289 (54%)
2–5 cm 192 (36%)
.5 cm 16 (3%)
Multifocal 38 (7%)
Prior surgical
procedure
Tumor intact (fine-needle
aspiration or core)
334 (62%)
Open biopsy 165 (31%)
Lumpectomy 34 (6%)
Unknown 2 (,1)
Tc99 preparation Filtered 211 (39%)
Unfiltered 321 (60%)
Unknown 3 (1%)
Gamma probe
used
C-trak 257 (48%)
Neoprobe 204 (38%)
Navigator 66 (12%)
Unknown 8 (2%)
Table 2. NUMBER OF PROCEDURES
WITH METASTASES
Sentinel
Nodes
Axillary Nodes
TotalPositive Negative
Positive 122 – 122
Negative 18 326 344
Total 140 326 466
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(30%) sentinel nodes found; 29% had three or more. There
was an increased chance (P 5 .025) of having a positive
sentinel node if more than one sentinel node was found
(Table 6). This translated into a lower false-negative rate
(see Table 5). The number of sentinel nodes found had no
bearing on the overall chance of having positive axillary
nodes or on the number of positive nodes (data not shown).
Factors affecting the number of sentinel nodes obtained
were examined, and the results are shown in Table 7. Older
patients were found to have significantly fewer sentinel
nodes. With increasing injection interval, the mean number
of sentinel nodes obtained increased (P 5 .01).
Characteristics of the sentinel nodes were available for
849 nodes. Sixty-four (7%) of these were blue only (radia-
tion activity less than 10 times background). Of the remain-
ing sentinel nodes, 57% were both hot and blue, and 36%
were hot only.
The relation between the number of sentinel nodes and
the experience of the surgeon is presented in Table 8 and
was not statistically significant. The data suggest that both
inexperience and number of sentinel nodes found may each
independently affect the false-negative rate. Using multi-
variate logistic regression, we found that the odds ratio for
inexperience after adjusting for the number of sentinel
nodes found was 5.2 (P 5 .064; likelihood ratio test).
The pattern of uptake of Tc99 by the sentinel node
differed depending on whether the Tc99 was filtered (Table
9). Because many patients had more than one sentinel node
and counts varied on each, calculations were made on both
the hottest node (mean hottest node counts) and all the
sentinel nodes (mean counts, all sentinel nodes). In the
unfiltered group, counts on the sentinel nodes increased
steadily with increasing time after Tc99 injection. In the
Table 3. SENTINEL NODE
IDENTIFICATION RATE
Variable
Identification
(%)
P
Value
Age (years)
,50 95.0
$50 84.6 .001
Prior surgery
Fine-needle aspiration/core biopsy 86.8
Open biopsy 90.6
Lumpectomy 81.8 .17
Tc99 Status
Filtered 87.3
Unfiltered 88.5 .68
Total positive nodes
,5 88.0
$5 75.0 .17
Injection time
,30 minutes 80.8
$30 minutes 88.8 .06
Tumor size
,2 cm 86.4
2–5 cm 89.0
.5 cm 87.5 .72
Tumor location
Inner 83.3
Outer 89.4
Central 94.4 .10
Surgeon experience
,10 cases 82.1
$10 cases 91.8 .002
Table 4. MULTIVARIATE ANALYSIS OF
FACTORS AFFECTING DECREASED
SUCCESS IN FINDING A SENTINEL NODE
Variable
Failure
Rate
Odds
Ratio
Odds Ratio
(95% CI)
Age (years)
,50 5.1 1.00
$50 15.4 3.46 1.31–9.22
Experience
.10 cases 8.2 1.00
#10 cases 17.9 2.72 1.30–5.71
Table 5. FACTORS AFFECTING
FALSE-NEGATIVE RATE
Variable
False-
Negative
Rate (%)
P
Value
Age (years)
,50 10.3
$50 15.1 .60
Prior surgery
Fine-needle aspiration/core biopsy 14.3
Open biopsy 11.4
Lumpectomy 11.1 .90
Tc99 status
Filtered 10.9
Unfiltered 15.0 .61
Total positive nodes
,5 12.2
$5 25.0 .20
Injection time
,30 minutes 17.2
$30 minutes 12.2 .54
Tumor size
,2 cm 17.3
2–5 cm 11.9
.5 cm 0.0 .43
Tumor location
Inner 30.0
Outer 6.9
Central 10.0 .02
Surgeon experience
,30 cases 15.5
$30 cases 4.0 .19
Number of sentinel nodes
1 20.8
$2 9.2 .07
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filtered group, however, the counts increased rapidly be-
tween 21 and 60 minutes and then decreased.
The positive SN was the hottest node in 77% of the
patients with a positive sentinel node in whom more than
one sentinel node was found. In 23% of the cases, however,
the positive node would have been missed if only the hottest
node had been removed.
DISCUSSION
Since the publication of the first series on SNB for breast
cancer,8 there has been overwhelming enthusiasm for de-
velopment of this technique. SNB represents a major ad-
vance because it is not only minimally invasive but also,
despite less surgery, improves the accuracy of pathologic
staging.9 This study was performed to delineate the factors
that are responsible for a false-negative sentinel node or
failure to identify a sentinel node when a combined Tc99
and IB technique is used. The investigators were from a
variety of centers and consisted of general surgeons as well
as breast specialists, so it is an excellent indicator of the
general utility of the technique. The results indicate that
caution must be used when performing SNB in older pa-
tients and patients with medial quadrant lesions. In addition,
it is clear from this data that the level of surgical expertise
with the technique is crucial. Performance of at least 30
cases is required to ensure that the success rate exceeds 90%
and the false-negative rate drops to less than 5%. The data
Figure 1. Adverse affects (decreased success rate of sentinel node biopsy) of increasing patient age.
Figure 2. Positive affects (decreased false-negative rate and increased success rate of sentinel node
biopsy) of increasing experience of the surgeon.
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do not support the conclusion that patients who have un-
dergone prior breast surgery or have a larger tumor are
ineligible for the procedure. These results, therefore,
broaden the applicability of the technique to patients who
have until now been excluded in most series.
It remains unclear whether the technique of using both IB
and Tc99 is superior to using either agent alone. The single
published multicenter trial using Tc99 alone5 included only
experienced surgeons and achieved a false-negative rate that
differed by 2% (11% vs. 13%) from this trial with relatively
inexperienced surgeons. The combination technique may
make it easier to find a sentinel node and reduce dissection
time, but proof of this would require further study. The
results of IB alone in experienced hands have been good.3,10
The concern with use of this agent alone, however, is that a
second sentinel node may be missed, whereas a second
radioactive sentinel node could be detected with the gamma
probe. In addition, the finding of a “cold axilla” provides
reassurance to the surgeon that all sentinel nodes have been
removed. The data from this trial suggest that surgeons
should not stop after finding just one sentinel node but
should search thoroughly to be certain there are not more.
This is especially appropriate because first, the mean num-
ber of sentinel nodes obtained in this trial was two, and
second, the false-negative rate in patients yielding one sen-
tinel node was 20.8% compared with 9.2% (P 5 .07) when
a second SN was sought and found.
In this large clinical trial with a relatively high false-
negative rate, we found that location of tumors in the medial
quadrant increased the false-negative rate. This finding is
baffling and with no obvious physiologic or anatomical
explanation; it may represent a statistical error in the small
population of patients with false-negative results. High
false-negative rates were found in patients in whom only
one sentinel node was found and with inexperienced sur-
geons, but these did not reach statistical significance. The
number of sentinel nodes found (see Table 8), after being
Table 6. NUMBER OF SENTINEL NODES
OBTAINED VERSUS RATE OF POSITIVITY
# Sentinel
Nodes Found # Pts.
# Pts. With
Positive Sentinel
Nodes
% Sentinel
Node Positivity
1 190 39 20.5
$2 276 83 30.0
P value .025
Table 7. FACTORS AFFECTING NUMBER OF SENTINEL NODES FOUND
Characteristic Variable
Mean # of
Sentinel Nodes
Found
P
Value
Tumor location Outer 2.08
Inner 1.71 .09
Central 2.32
Prior surgical procedure Tumor intact (fine-needle aspiration or core) 1.96
Open biopsy 2.08 .34
Lumpectomy 1.59
Tc99 preparation Filtered 1.96
Unfiltered 2.00 .79
Gamma probe used C-trak 1.93
Neoprobe 2.00
Navigator 2.18 .59
Age at diagnosis (years) ,50 2.51
$50 1.74 .001
Injection interval (min) ,20 1.57
21–60 1.61
61–240 2.21 .01
.240 1.89
Table 9. TIMING OF Tc99 AND EX VIVO
SENTINEL NODE COUNTS USING
FILTERED AND UNFILTERED
PREPARATIONS
Timing of Tc99
(min)
Mean Hottest Node
Counts
Mean Counts
All Sentinel
Nodes
Filtered
,20 2,938 2,609
21–60 24,558 11,563
61–240 4,629 3,583
.240 1,863 1,519
Unfiltered
,20 2,683 1,816
21–60 3,332 1,937
61–240 9,178 5,142
.240 8,683 5,886
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adjusted for inexperience, was significant (P 5 .005; like-
lihood ratio test). Although with only 18 false-negative
results, the power of these results is limited, they are inter-
esting from the standpoint that the large adjusted odds ratio
for inexperience suggested that the inexperience effect is
not solely due to inexperienced surgeons finding fewer
sentinel nodes. Because the actual number of patients with
a false-negative result is small, an even larger series of
patients will be required to determine definitively which
factors can predict a false-negative result.
Various injection techniques have been described,2,11–13
and it is not clear whether one is optimal. These techniques
include peritumoral injection, subdermal injection, and in-
jection of Sappey’s plexus. As the area of the peritumoral
injection increases (i.e., compare the injection area of a
small biopsy to a lumpectomy), the number of sentinel
nodes obtained might increase. If the injection technique
leads to finding a large number of sentinel nodes, this
ultimately dilutes the sentinel node concept. Some studies
have found a lower success rate in patients who have
undergone a prior breast biopsy,5,14,15 and others have
not.3,16 We found that removing breast tissue for either a
breast biopsy or a therapeutic lumpectomy did not statisti-
cally alter either the false-negative rate or the identification
rate. These results support the hypothesis that perhaps the
entire breast drains to only one or two sentinel nodes. This
is further supported by not finding a greater number of
sentinel nodes in patients who had a prior biopsy or lumpec-
tomy (see Table 7). If confirmed in larger series, these data
would suggest that precise injection of IB or Tc99 at the
tumor site might not be necessary.
In this study, the affect of increasing patient age was
significant. Not only were fewer sentinel nodes found, but
they were also found less frequently. Krag et al5 reported a
similar finding and hypothesized that this was secondary to
the progressive replacement of the parenchyma of the
lymph nodes in older patients by fat. It is also possible that
with increasing age, the breast becomes progressively re-
placed by fat and the lymphatic vessel density decreases.
Lymphatic uptake of the dye and Tc99 may become more
sluggish, resulting in less concentration of the Tc99 or IB in
the sentinel node, making sentinel node identification more
difficult. Further research will be needed to formulate better
techniques to guarantee a high success rate in the elderly
population.
It has been hypothesized that as the tumor volume in the
axilla increases, the success rate of SNB decreases and the
false-negative rate increases. The biologic rationale behind
this hypothesis is that lymphatics become progressively
infiltrated with tumor cells and do not allow the passage of
dyes or radionucleotides. Our identification rate was lower
when patients had five or more involved axillary nodes, but
this did not reach statistical significance. The small number
of patients with more than five positive axillary nodes could
account for this. The success rate was also lower in patients
with tumor lymphovascular invasion (80% vs. 87%). Until
larger series confirm extent of axillary involvement as an
important factor, it is probably wise in patients undergoing
SNB alone, especially those in whom a clinical examination
is difficult (i.e., obese patients), to perform intraaxillary
palpation through the SNB incision. Any suspicious lymph
nodes should be biopsied. The possibility of obtaining a
false-negative result in a patient with bulky disease in the
axilla is worrisome because that patient would be at high
risk of systemic failure and might be denied chemotherapy
based on the false results of the sentinel node. The patient
would also be denied any possible therapeutic benefit of
removing malignant lymph nodes.
We previously showed in an animal model of lymphatic
mapping that use of filtered versus unfiltered Tc99 resulted
in finding more sentinel nodes.7 This was not the case in this
trial. Confounding factors making this comparison difficult
are the different injection techniques used (peritumoral vs.
subdermal) and a probable inherent difference between the
swine and human lymphatic systems. We did find, however,
less variation in gamma probe counts when the unfiltered
preparation was used. Because neither preparation affected
the false-negative rate or success rate, it is unlikely to be an
important factor in the technique of lymphatic mapping with
experienced surgeons. It may, however, be an important
factor in decreasing the learning curve of sentinel node
identification. The hotter the sentinel node, the easier it is to
detect at the skin level. To obtain this using filtered takes a
short injection time interval (30–60 minutes), whereas a
longer injection interval may be more optimal for use of
unfiltered Tc99 (60–240 minutes).
Medial quadrant tumors have posed several concerns and
questions with the introduction of lymphatic mapping for-
breast cancer. In some patients, a medial quadrant lesion
drains to the internal mammary nodes, producing metasta-
ses in this lymphatic chain.17–19 Data from early random-
ized trials showed that removal of these lymph nodes could
increase survival (at the cost of many complications).20
SNB has the potential to identify the group of patients at
risk for these metastases by identifying an internal mam-
mary sentinel node. Dissection of internal mammary senti-
nel nodes was extensively studied in one series using 10
mCi radiocolloid with excellent results.16 Seventy patients
were described, and 34% of patients undergoing lympho-
Table 8. EXPERIENCE VERSUS NUMBER
OF SENTINEL NODES
Experience
One Sentinel
Node
Two Sentinel
Nodes
Three Sentinel
Nodes
,30 cases 23 (9/39) 18 (7/39) 3 (1/32)
$30 cases 11.1 (1/9) 0 (0/6) 0 (0/10)
P value .39 .26 .57
Data given represent the false-negative rate, with number of cases in parentheses.
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scintigraphy were found to have an internal mammary sen-
tinel node (n 5 24). These were successfully dissected in
62% (15/24) of the patients and were found to be positive in
33% (5/15). Two patients had a pneumothorax. In our trial,
a much lower percentage of patients (16%) were found to
have a hot spot at the internal mammary basin with counts
10 times the background count, but dissection was not
performed. The difference in the rate could be attributed to
the lower dose of Tc99 used in this clinical trial. It is
difficult to determine whether these hot spots represent true
internal mammary sentinel nodes or “shine-through” from a
hot primary close to this chain of lymph nodes. The inci-
dence of internal mammary metastases is low, and therefore
a clinical trial to evaluate the therapeutic benefit of either
positive internal mammary sentinel node removal or treat-
ment of positive internal mammary nodes with radiation
would be difficult. For the first time, however, it is possible,
with minimal complications, to tailor treatment for patients
at risk for metastases in this chain of lymph nodes.
In summary, the combined use of IB and Tc99 can
identify sentinel nodes accurately but requires surgical ex-
pertise to reach what has been viewed as an acceptable level
of success and an acceptable false-negative rate (.85% and
,5%, respectively).21 These data suggest that caution is
required in older patients and in patients with medial quad-
rant lesions. Our results, however, also demonstrate the
usefulness of SNB even in patients with larger tumors and
those who have undergone prior breast surgery. Other fac-
tors beyond the surgeon’s control, such as a large axillary
tumor burden, may contribute to SNB failure. Progression
to performing SNB alone by the surgical community will
need to be accompanied by a thorough intraaxillary exam-
ination to attempt to decrease the false-negative rate. Al-
though it is not well established what false-negative rate, if
any, will translate into decreased survival, the technique
will spare more than half of patients an axillary node dis-
section, which carries significant complications and pro-
vides no benefit when the lymph nodes are negative.
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